Aptevo Therapeutics (NASDAQ:APVO) Trading Up 3% – Should You Buy?

Aptevo Therapeutics Inc. (NASDAQ:APVO)’s share price shot up 3% during trading on Thursday . The stock traded as high as $4.86 and last traded at $4.86. 15,800 shares changed hands during trading, a decline of 54% from the average session volume of 34,356 shares. The stock had previously closed at $4.72.

Analyst Ratings Changes

Several research firms have recently commented on APVO. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 29th. Weiss Ratings cut Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Aptevo Therapeutics currently has an average rating of “Hold”.

Aptevo Therapeutics Trading Up 3.0%

The firm has a market capitalization of $6.08 million, a price-to-earnings ratio of -0.02 and a beta of 1.68. The company has a 50-day moving average of $4.83 and a 200-day moving average of $8.69.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($6.41). On average, research analysts forecast that Aptevo Therapeutics Inc. will post -24.13 earnings per share for the current year.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.